Deep Apple Therapeutics Fuels the Future of Drug Discovery with $52M Series A Funding

Deep Apple Therapeutics is excited to announce a significant milestone in its innovative journey with the successful closing of a US$52 million funding round. This pivotal investment underscores the strong confidence from our investors in our disruptive approach to drug discovery, which harnesses the power of cutting-edge technologies and high-performance scientific methods. Within a vast and unexplored virtual chemical space, we are racing against conventional timelines and limitations to identify novel small molecules that can tackle high-value targets. Our advanced method integrates ensemble cryo-EM to capture receptor conformations, deep learning algorithms to sift through complex data, and the docking of multi-billion compound libraries generated via our proprietary Orchard.ai™ algorithm. This funding will fuel our efforts to expand our groundbreaking deep learning discovery engine, built upon decades of expertise in computational modeling, protein and target structure determination, and dynamic molecular docking. With these new resources, we are set to further accelerate the progression of promising candidates targeting well-validated pathways in inflammatory, metabolic, and endocrine diseases. The strategic injection of capital not only enables us to scale our operations but also positions us to dive even deeper into the chemical spaces that are critical for developing next-generation therapies. As we continue to push boundaries in structure-based drug design, our aim remains clear: to deliver transformative solutions for patients with unmet medical needs. For more information about our work and vision, please visit deepappletx.com. This funding marks an exhilarating chapter for Deep Apple Therapeutics, reaffirming our leadership in pioneering a future where high-speed, high-precision discovery translates into real-world medical breakthroughs.